Real-World Prevalence of PD-L1 Expression in Chinese Patients with Advanced or Metastatic NSCLC: Express II Study

被引：0
|
作者：
Lin, D. [1 ]
Yang, X. [1 ]
Jiang, L. [2 ]
Wang, W. [2 ]
Hou, Y. [3 ]
Li, Y. [4 ]
Jin, Y. [4 ]
Fan, X. [5 ]
Sun, W. [6 ]
Yun, J. [7 ]
Li, P. [7 ]
Kuang, D. [8 ]
Zhang, L. [9 ]
Ni, J. [10 ]
Mao, A. [11 ]
Tang, W. [11 ]
Liu, Z. [11 ]
Wang, J. [11 ]
Xiao, S. [11 ]
机构：
[1] Beijing Canc Hosp, Beijing, Peoples R China
[2] Sichuan Univ, West China Hosp, Chengdu, Peoples R China
[3] Fudan Univ, Zhongshan Hosp, Shanghai, Peoples R China
[4] Fudan Univ, Shanghai Med Coll, Dept Pathol, Shanghai, Peoples R China
[5] Nanjing Drum Tower Hosp, Nanjing, Peoples R China
[6] Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China
[7] Sun Yat Sen, Canc Hosp, Guangzhou, Peoples R China
[8] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Shanghai, Peoples R China
[9] Shanghai Pulm Hosp, Shanghai, Peoples R China
[10] First Hosp Jilin Univ, Eastern Div, Changchun, Peoples R China
[11] Bldg A,Headquarters Pk Phase 2,1582 Gumei Rd, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Non-small cell lung cancer; programmed death-ligand 1; IHC;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P33.12
引用
收藏
页码：S410 / S410
页数：1
相关论文
共 50 条
  • [1] Real-world prevalence of PD-L1 expression in locally advanced or metastatic non-small cell lung cancer (NSCLC): The global, multicentre EXPRESS study
    Dietel, M.
    Savelov, N.
    Salanova, R.
    Micke, P.
    Bigras, G.
    Hida, T.
    Piperdi, B.
    Burke, T.
    Khambata-Ford, S.
    Deitz, A.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S74 - S75
  • [2] Real-World Prevalence of PD-L1 Expression in Advanced NoneSmall-Cell Lung Cancer: The Global, Multicenter EXPRESS Study
    Salanova, R.
    Dietel, M.
    Savelov, N.
    Micke, P.
    Bigras, G.
    Hida, T.
    Piperdi, B.
    Burke, T.
    Khambata-Ford, S.
    Deitz, A.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S155 - S156
  • [3] PD-L1 expression affect the efficacy of pemetrexed maintenance therapy in real-world patients with advanced non-squamous NSCLC
    Qin, Y.
    Jiang, L.
    Li, Y.
    Ren, L.
    Wang, Y.
    Gong, Y.
    Peng, F.
    Zhu, J.
    Ding, Z.
    Liu, Y.
    Yu, M.
    Lu, Y.
    Huang, M.
    ANNALS OF ONCOLOGY, 2019, 30
  • [4] PD-L1 expression and its significance in advanced NSCLC: real-world experience from a tertiary care center
    Kilaru, Sindhu
    Panda, Soumya Surath
    Moharana, Lalatendu
    Mohapatra, Debahuti
    Mohapatra, Satya Sundar G.
    Panda, Adyakinkar
    Kolluri, Spoorthy
    Devaraj, Suma
    Biswas, Ghanashyam
    JOURNAL OF THE EGYPTIAN NATIONAL CANCER INSTITUTE, 2024, 36 (01)
  • [5] PD-L1 expression and its significance in advanced NSCLC: real-world experience from a tertiary care center
    Sindhu Kilaru
    Soumya Surath Panda
    Lalatendu Moharana
    Debahuti Mohapatra
    Satya Sundar G. Mohapatra
    Adyakinkar Panda
    Spoorthy Kolluri
    Suma Devaraj
    Ghanashyam Biswas
    Journal of the Egyptian National Cancer Institute, 36
  • [6] 5-Year Real-World Outcomes With Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC
    Velcheti, Vamsidhar
    Rai, Pragya
    Kao, Yu-Han
    Chirovsky, Diana
    Nunes, Ana Tablante
    Liu, Stephen, V
    CLINICAL LUNG CANCER, 2024, 25 (06)
  • [7] Real-world treatment patterns and immunotherapy (IO) sequencing based on PD-L1 TPS in European patients with metastatic NSCLC
    Janowicz, E.
    Ognar, R.
    Anderson, D.
    Capart, P.
    Stoyanov, N.
    Nguyen, B.
    Combest, A.
    ANNALS OF ONCOLOGY, 2020, 31 : S853 - S853
  • [8] Pembrolizumab monotherapy in advanced NSCLC patients with low PD-L1 expression: is there real evidence?
    Fiorelli, Alfonso
    Vitiello, Fabiana
    Morgillo, Floriana
    Santagata, Mario
    Spuntarelli, Chiara
    Di Domenico, Marina
    Santini, Mario
    Bianco, Andrea
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S618 - S620
  • [9] REAL-IMPACT: Real-World Effectiveness of Immunotherapy in PD-L1 Negative Advanced NSCLC A Multicenter Cohort Study in Argentina
    Picon, C. R.
    Rizzo, M. M.
    Sanchez del Cid, M.
    Amorin, R.
    Tsou, F.
    Castro, N.
    Garcia, M. B.
    Cheng, S.
    Scocimarro, A.
    Rapaccioli, M.
    Castagneris, N.
    Malcervelli, G.
    Levit, P.
    Carranza, O.
    Piazzoni, L.
    Kaen, D.
    Ayala, N.
    Martin, C.
    Lupinacci, L.
    Puparelli, C.
    Basbus, L.
    Enrico, D.
    Garcia Giner, B.
    Perfetti, A.
    Vera, K.
    Bluthgen, V.
    Sena, S.
    Riso, A.
    Gayet Preiss, F.
    Kowalyszyn, R.
    Barbaro, F.
    Santa Cruz, M. A.
    Bastida, N.
    Minatta, J. N.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S605 - S606
  • [10] Real-World Effectiveness of Nivolumab by PD-L1 Expression in NSCLC pts in Japan: A Multicenter-Retrospective Study
    Kim, Young Hak
    Morita, Ryo
    Okishio, Kyoichi
    Simizu, Junichi
    Saito, Haruhiro
    Sakai, Hiroshi
    Hataji, Osamu
    Yomota, Makiko
    Nishio, Makoto
    Aoe, Keisuke
    Kanai, Osamu
    Kumagai, Toru
    Kibata, Kayoko
    Tsukamoto, Hiroaki
    Oizumi, Satoshi
    Tomii, Keisuke
    Tanaka, Hiroshi
    Mizuno, Keiko
    Hoshiyama, Hirotoshi
    Ochi, Kenya
    Ohe, Yuichiro
    ANNALS OF ONCOLOGY, 2019, 30
12345